DelveInsight Business Research LLP The type 2 diabetes market is expected to witness steady growth, driven by the rising global prevalence of diabetes, increasing rates of obesity and sedentary lifestyles, and growing awareness of early diagnosis and disease management. The expanding use of newer therapies, including GLP-1 receptor agonists, dual and triple incretin-based treatments, SGLT2 inhibitors, and other novel glucose-lowering agents, is further supporting market expansion. Additionally, the launch of emerging therapies such as agriSema (Novo Nordisk), Survodutide (BI 456906; Boehringer Ingelheim), Retatrutide (Eli Lilly), ASC30 (Ascletis Pharma), and others will further drive the market growth upward. New York, USA, Oct.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.